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Abstract:  Tobacco  use  is  a  major  public  health  problem  worldwide.  Tobacco-related 
cancers cause millions of deaths annually. Although several tobacco agents play a role in the 
development of tumors, the potent effects of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
(NNK)  and  N'-nitrosonornicotine (NNN)  are  unique. Metabolically activated NNK and 
NNN induce deleterious mutations in oncogenes and tumor suppression genes by forming 
DNA adducts, which could be considered as tumor initiation. Meanwhile, the binding of 
NNK  and  NNN  to  the  nicotinic  acetylcholine  receptor  promotes  tumor  growth  by 
enhancing and deregulating cell proliferation, survival, migration, and invasion, thereby 
creating a microenvironment for tumor growth. These two unique aspects of NNK and 
NNN  synergistically  induce  cancers  in  tobacco-exposed  individuals.  This  review  will 
discuss  various  types  of  tobacco  products  and  tobacco-related  cancers,  as  well  as  the 
molecular mechanisms by which nitrosamines, such as NNK and NNN, induce cancer. 
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Abbreviations 
NNK  4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone 
NNN  N'-nitrosonornicotine 
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NNAL  4-(methylnitrosoamino)-1-(3-pyridyl)-1-butan-1-ol 
PAH  polycyclic aromatic hydrocarbons 
POB  pyridyloxobutyl 
PHB  pyridylhydroxybutyl 
O6mGua  O
6-methylguanine 
O4-mTh  O
4-methylthymine 
7-mGua  7-N-methylguanine 
AGT  O
6-alkylguanine DNA-alkyltransferase 
1. Introduction 
Tobacco use is an epidemic and a global public health problem. One in three cancer-related deaths 
is attributable to tobacco use in the United States [1]. Approximately 1 billion men and 250 million 
women  are  smokers  worldwide  [2,3].  Tobacco  use  is  declining  in  most  industrialized  countries,  
but overall consumption is increasing with approximately 5.5 trillion cigarettes smoked each year [2], 
driven  in  part  by  substantial  widespread  use,  population  growth,  and  economic  development  [4].  
In the United States, tobacco contributes to the preventable and premature deaths of an estimated 443,000 
Americans each year [5]. The World Health Organization estimates, based on the trend of longevity, 
current smoking trends and increasing adoption of unhealthy lifestyles, that the annual death toll will 
exceed to 12 million and that there will be 15 million new cancer cases diagnosed annually by 2020 [6]. 
Tobacco products contain a diverse array of chemicals, including nicotine and carcinogens. The 
combination of nicotine and these carcinogens is devastating and responsible for millions of preventable 
and premature deaths worldwide. The impact of tobacco on human health varies depending on the 
types of tobacco products used and the duration of lifetime exposure. Smokers are exposed to tobacco 
products primarily by smoking manufactured and/or hand-rolled cigarettes. Non-smokers are exposed 
to tobacco smoke from the environment, where cigarette smoking occurs. This exposure is known as 
secondhand,  involuntary,  passive  or  environmental  exposure.  Men  and  women  can  be  exposed  to 
tobacco  by  consumption  of  smokeless  tobacco.  Nicotine  is  the  principal  property  of  all  types  of 
tobacco products and smoke. Nicotine is addictive and non-carcinogenic [7]; however, it is capable of 
activating various signaling pathways related to tumor promotion [8]. In addition, tobacco products 
contain carcinogens, including nicotine-derived nitrosamines, which cause cancer or pose risk of cancer in 
animals  and  humans  [9–12].  Nitrosamines  such  as  4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
(NNK) and N'-nitrosonornicotine (NNN), are carcinogenic to humans [13]. NNK and NNN induce 
carcinogenesis by causing DNA adductions and mutations as well as promoting tumor growth through 
receptor-mediated  effects  [3,14].  Exposure  and  consumption  of  tobacco  products  are  causally 
associated with various types of cancers [8–12]. Nicotine and nitrosamines form a devastating and fatal 
alliance.  Nicotine  activates  the  brain’s  reward  system,  eliciting  cravings  for  continued  tobacco 
consumption, and it often is accompanied by carcinogens inducing tumor initiation and progression. 
Tobacco  smoking  causes  30%  of  all  cancer  mortality  in  developed  countries  [15],  and  smokeless 
tobacco use is a major cause of cancer in the developing world, particularly southern Asia [13,16]. 
Exposure to tobacco smoke, secondhand smoke, and/or smokeless tobacco consumption is causally 
associated with various cancers, for instance, cancers of respiratory, digestive, and urinary systems. Cancers 2014, 6 
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This review will describe types of tobacco smoke and tobacco-related cancers and focus on certain 
molecular mechanisms by which nitrosamines induce carcinogenesis. 
2. Tobacco 
Tobacco  use  is  epidemic  and  contributes  to  preventable  morbidity  and  mortality  worldwide.  
There is convincing evidence that tobacco use is causally associated with various cancers [17]. The 
following describes the association of different types of tobacco use and cancers. 
2.1. Tobacco Smoke 
Tobacco smoking is the leading cause of cancer-related death in the world, having been associated 
to  approximately  1.2  million  deaths  annually,  and  it  is  linked  to  90%  of  lung  cancer  cases  [18]. 
Tobacco smoke, derived from combustion of manufactured or hand-rolled cigarettes, contains at least 
7000  chemicals  [9–12,19].  While  nicotine  is  generally  accepted  as  non-carcinogenic,  it  is  always 
accompanied in tobacco by carcinogens [7]. Tobacco smoke contains a number of carcinogens known 
to cause cancers in animals and humans [18]. These carcinogens are derived from various chemical 
classes such as polycyclic aromatic hydrocarbons (PAHs), nitrosamines (i.e., NNK, NNN), aromatic 
amines, aldehydes, phenols, volatile hydrocarbons, nitro compounds, and other organic and inorganic 
compounds [3,18]. Nicotine also promotes cancer by activating signaling pathways facilitating cancer 
cell growth, angiogenesis, migration, and invasion [8]. Nicotine can undergo chemical conversions 
into carcinogenic NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and NNN during the 
process  of curing  or  smoking  [7,20].  The  majority  of  nicotine can  be  metabolized  to  cotinine  by 
cytochrome P450 (CYP) 2A6, CYP2B6, and aldehyde oxidase [7,20], and the remaining nicotine may 
be converted to other metabolites such as nicotine-N-oxide (NNO) [7,20]. Nicotine and nitrosamines 
(i.e., NNK, NNN,) are implicated in tumor promotion by activating nicotinic acetylcholine receptors 
(nAChRs) and β-adrenergic receptors (β-AdrRs), leading to downstream activation of parallel signal 
transduction pathways that facilitate tumor progression [8]. 
Tobacco  smoke  is  causally  linked  to  lung  cancer,  laryngeal,  oropharyngeal,  hypopharyngeal, 
esophageal, stomach, liver, pancreas, bladder, and ureter cancers and renal pelvis and renal-cell carcinoma, 
squamous-cell cervical carcinoma, and myeloid leukemia [18,21]. Cigarette smoking also increases the 
risk  of  cancers  for  sinonasal,  nasopharyngeal,  oral  cavity,  and  colorectal  cancers  [21].  Cigarette 
smokers  have  a  higher  risk  of  developing  advanced  stage  and  high-grade  prostate  cancer,  which 
generally indicates a poor prognosis [22]. 
2.2. Secondhand Tobacco Smoke 
Secondhand tobacco smoke is also known as environmental tobacco smoke, involuntary smoke and 
passive smoke. Non-smokers can be exposed to secondhand smoke from different sources, such as in 
the home, the workplace and outside public buildings. Chemicals similar to those found in direct 
tobacco smoke have been identified in secondhand tobacco smoke, and out of these, 250 are known to be 
harmful to human health At least 69 chemicals in secondhand tobacco smoke are carcinogens [12,23–25]. 
Secondhand tobacco smoke also contains nicotine and carcinogens such as nitrosamines (i.e., NNN Cancers 2014, 6 
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and NNK) [18]. Sidestream smoke (previously uninhaled smoke, e.g., smoke from the burning tip of 
the  cigarette)  and  mainstream  secondhand  smoke  (smoke  that  has  been  inhaled  and  then  exhaled  
into the environment) are different in their physicochemical properties [18]. The ratios of sidestream  
to  mainstream  smoke  vary  largely  depending  on  the  constituents  of  tobacco  products  from  
different manufacturers. For example, nicotine, NNK, and NNN ratios can be 7.1, 0.40, and 0.43, 
respectively [18]. Secondhand tobacco smoke is causally associated with lung cancer in non-smoking 
adults [12,24]. In the United States, approximately 3000 lung cancer deaths each year among adult 
non-smokers are associated with exposure to secondhand smoke [26]. Secondhand tobacco smoke is 
linked to the increased risk of breast cancer, nasal sinus cavity cancer, and nasopharyngeal cancer in 
adults and the risk of leukemia, lymphoma, and brain tumors in children [24,26]. 
2.3. Smokeless Tobacco 
Smokeless tobacco is unburned tobacco, and is also known as chewing tobacco, oral tobacco, spit 
or spitting tobacco, dip, and snuff. Users chew or suck the tobacco in their mouth and spit out the juice 
of the tobacco [27]. Nicotine and other chemical compounds are absorbed through the lining of the 
mouth.  Chemical  composition  of  smokeless  tobacco  products  varies  depending  on  brands  and 
manufacturers. Smokeless tobacco has been considered as a potentially reduced risk substitute for 
tobacco smoking; however, a study by Hecht et al. demonstrates that there is similar exposure to the 
tobacco-specific carcinogen NNK in smokers and smokeless tobacco users [28]. Smokeless tobacco 
products contain nicotine [29,30] and carcinogens. At least 28 carcinogens, including nitrosamines 
(i.e.,  NNK  and  NNN),  are  identified  in  smokeless  tobacco  products  [3,13].  Smokeless  tobacco  is 
causally associated with oral, esophageal, and pancreatic cancers [13]. 
3. Tobacco-Specific Carcinogens 
3.1. Carcinogens 
Tobacco products contain a diverse array of chemical carcinogens that cause cancers of various 
types. To date, more than 60 carcinogens in cigarette smoke have been identified and evaluated by the 
International Agency for Research on Cancer [31]. Among them, tobacco-specific nitrosamines (such 
as NNK and NNN), PAHs (such as benzo[a]pyrene) and aromatic amines (such as 4-aminobiphenyl) 
are the prominent carcinogens that have been verified in animal models and positively identified in 
cigarette smoke [32,33]. Nitrosamines in tobacco products are formed by nitrosation of nicotine and 
related tobacco alkaloids. The terms NNK for ―nicotine-derived nitrosaminoketone‖ and NNA for 
―nicotine-derived nitrosaminoaldehyde‖ were devised to emphasize their relationship to NNN via the 
common  precursor  nicotine  [34].  Seven  tobacco-specific  nitrosamines,  i.e.,  NNN,  NNK,  NNAL,  
N'-nitrosoanabasine  (NAT),  1-nitrosoanabasine  (NAB),  iso-NNAL,  and  4-(methylnitrosamino)-4-3-
pyridyl)butyric acid, have been identified in tobacco products. NNN, NNK, and NAT generally occur 
in  quantities  greater  than  the  other  compounds.  NNN,  NNK,  and  NNAL  are  evidently  the  most 
carcinogenic of these compounds [34–38]. NNK and NNN will be the focus of this review. Cancers 2014, 6 
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3.2. Molecular Mechanisms of Nitrosamine-Induced Cancer 
3.2.1. NNK and NNN Modulated Tumor Initiation: A Battle between DNA-Adducts Formation and Removal 
Naturally  occurring  NNK  in  tobacco  smoke  is  a  procarcinogen,  an  inert  form  that  
requires  metabolic  activation  to  exert  its  carcinogenic  functions  [39–42].  Multiple  CYPs  activate  
NNK  to  DNA-reactive  metabolites  that  can  induce  the  methylation,  pyridyloxobutylation  and 
pyridylhydroxybutylation of nucleobases in DNA and form DNA adducts (Figure 1). α-Methylene 
hydroxylation of NNK yields methane diazohydroxide [43] and/or the methyldiazonium ion, which 
reacts with DNA producing mainly 7-N-methylguanine (7-mGua) and O
6-methylguanine (O6-mGua) 
as  well  as  small  amounts  of  O
4-methylthymine.  α-Hydroxylation  of  NNK  can  occur  either  at  the 
methyl or methylene carbon. α-Hydroxylation at the methyl carbon produces α-hydroxymethyl NNK, 
which is stable enough to undergo glucuronidation [44]. It spontaneously loses formaldehyde producing 
a pyridyloxobutyldiazohydroxide, which reacts with DNA yielding bulky pyridyloxobutylation  (POB) 
adducts [36]. Four of these have been identified. They are 7-[4-(3-pyridyl)-4-oxobut-1-yl]-2'-deoxyguanosine, 
O
2-[4-(3-pyridyl)-4-oxobut-1-yl]-2'-deoxycytosine,  O
2-[4-(3-pyridyl)-4-oxobut-1-yl]-2'-deoxythymidine 
(O
2-pobdT)  and  O
6-[4-(3-pyridyl)-4-oxobut-1-yl]-2'-deoxyguanosine  (O
6-pobdG)  [45].  Figure  1 
illustrates schematically NNK and NNN metabolisms and DNA adduct formation. 
Figure  1.  Schematic  illustration  of  the  pathways  of  NNK  and  NNN  metabolism  and  
DNA  adduct  formation  as  determined  by  studies  in  laboratory  animals  and  humans.  
NNK: 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, NNN: N'-nitrosonornicotine. 
 
Reduction  of  the  NNK  carbonyl  group  by  carbonyl  reductases  produces  NNAL,  which  is  the 
predominant NNK metabolite formed in vitro. 11-β-Hydroxysteroid dehydrogenase (EC 1.1.1.146),  
a  microsomal  enzyme  responsible  for  the  interconversion  of  active  11-hydroxyglucocorticoids  to Cancers 2014, 6 
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inactive 11-oxo forms, has been identified as one of the carbonyl reductases involved in the reduction 
of NNK to NNAL. Whether this is the major enzyme responsible for NNK reduction in mammals is 
not known [46]. NNAL is metabolically transformed in ways similar to that of NNK [34]. 
Animal studies have shown that NNN specifically causes esophageal and nasal tumors in rats and 
respiratory tract tumors in mice and hamsters [47–49]. Three types of reactions have been observed in 
NNN metabolism pathways: pyridine N-oxidation, hydroxylation of the pyrrolidine ring (including  
α-hydroxylation  at  the  2'-  and  5'-positions  and  β-hydroxylation  at  the  3'-  and  4'-positions)  and 
norcotinine formation [34]. The 2'- and 5'-α-hydroxylation pathways are the major pathways leading to 
the formation of DNA adducts. 2'-Hydroxy NNN undergoes spontaneous ring opening to produce a 
pyridyloxobutyldiazohydroxide  identical  in  structure  to  that  formed  upon  methyl  hydroxylation  of 
NNK. 5'-Hydroxylation also yields an electrophilic diazohydroxide, which is expected to react with 
DNA [39], and the α-hydroxylation reactions of NNN are catalyzed predominantly by CYPs [50]. 
Although DNA adduct formation is considered the central step in the process of NNK and NNN 
carcinogenesis, the capacity of various DNA adducts to induce mutations and chromosomal aberrations 
varies extensively (Figures 1 and 2). O
6-mGua is a highly pro-mutagenic adduct causing G:C to A:T 
transitions [51,52]. O
6-mGua adducts can be removed by the DNA repair protein, O
6-alkylguanine 
DNA-alkyltransferase  (AGT;  also  known  as  MGMT)  or  AlkB  homologs.  AGT  overexpression  in 
transgenic  mice  reduces  the  formation  of  K-ras  GC→AT  mutations  and  tumors  induced  by 
methylating agents [53]. 7-mGua is rapidly removed by base excision repair (BER) as well as by 
spontaneous depurination. The latter gives rise to apurinic sites that are prone to undergo rapid and 
error-free repair [54]. In contrast to O
6-mGua, 7-mGua seems to have low mutagenic potency, because 
there was no correlation between persistence of 7-mGua adduct levels from NNK and incidence of liver 
tumors in rodents [55]. O
6-pobdG has been shown to be efficiently repaired by AGT both in vitro [56] 
and  in  vivo  [57].  If  not  repaired,  O
6-pobdG  adducts  induce  large  numbers  of  G→A  and  G→T 
mutations [58]. 
Although  pyridyloxobutyl  DNA  adducts  may  also  be  repaired  by  nucleotide  excision  repair  
(NER) [59] as well as by BER pathways [60], there is no direct evidence for the role of BER in the 
repair of pyridyloxobutyl DNA damage. However, loss of X-ray repair cross-complementing protein 1 
(XRCC1), an important scaffold protein in BER [61], increases the mutagenic and toxic effects of  
4-(acetoxymethylnitrosamino)-1-(3-pyridyl)-1-butanone (NNKOAc) [60], which indicates that XRCC1 
plays an important role in protecting cells against the harmful effects of these adducts. Similar to BER, 
loss of xeroderma pigmentosum complementation group A and group C (XPA and XPC), two important 
components in the NER pathway, reduce the rate of incorporation of [α-
32P] thymidine 5'-triphosphate 
into NNKOAc treated plasmid DNA when assayed in NER-deficient cell lysate [62,63]. O
2-pobdT was 
the only adduct whose removal was affected by the loss of excision repair cross-complementing-2 
(ERCC-2  also  known  as  XPD),  an  essential  protein  in  the  NER  pathway  [64].  Its  repair  was 
significantly slower in the absence of ERCC-2 suggesting the importance of NER in the removal of 
this adduct [60]. Cancers 2014, 6 
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Figure 2. Two essential aspects of NNK- and NNN-induced cancer. Metabolic activated 
NNK and NNN induce DNA adducts, which can be eliminated by functional DNA repair 
networks.  Unresolved  DNA  adducts  further  cause  mutations  in  oncogenes  and  tumor 
suppressor genes, which consists of the first step of NNK and NNN specific carcinogenesis. 
Binding of NNK and NNN to nAChRs promote tumor growth by enhancing and deregulating 
cell proliferation, cell survival and cell migration as well as cell invasion, which is the 
second step of NNK- and NNN-induced cancer. The combination of these two aspects of 
the biological reactions of NNK and NNN provide the condition for tumor development in 
smokers. NNK: 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, NNN: N'-nitrosonornicotine. 
 
Experimental data has suggested that a multistep process of genetic alterations is responsible for 
NNK- and NNN-induced carcinogenesis. DNA adducts that are misrepaired or not repaired constitute 
a necessary, although not sufficient, prerequisite for induction of cancer. Initiation and progression of 
tumorigenesis, however, is complex and involves inactivation of tumor suppressor genes, activation  
of  oncogenes,  inflammatory  processes  as  well  as  alterations  in  the  tissue  microenvironment.  
Fewer than 20% of smokers will get lung cancer. Susceptibility depends in part on the balance between 
carcinogen metabolic activation and detoxification in the smokers [65]. The genetic polymorphisms  
in  carcinogen-activating  genes  as  well  as  in  DNA  repair  genes  are  important  determinants  of  
DNA-adduct levels. DNA repair system sets up the second defense line required for eliminating or 
repairing the lesions of DNA adducts in the genome from the insults of NNK or NNN. An impaired Cancers 2014, 6 
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DNA repair system would constitute a significant risk factor for smoking-related cancers. NNKOAc 
was more cytotoxic in cell lines lacking AGT, BER and NER repair pathways. It also induced more 
mutations in the hypoxanthine phosphoribosyltransferase gene in BER- and NER-deficient cell lines [60]. 
Polymorphisms in the DNA repair gene XRCC1 significantly increase the genotoxicity induced by 
NNK [66]. Polymorphisms in ERCC-2 limit DNA repair efficiency in humans leading to increased 
frequencies of chromosome aberration in their lymphocytes. Elevations in NNK-induced aberrations 
were significantly associated with the 312Asn allele. The risk was higher in smokers [67]. 
Oxidative stress occurs when the productions of oxidant species (mostly reactive oxygen species 
(ROS) and reactive nitrogen species (RNS) exceed the cellular neutralizing capabilities. The mitochondrial 
respiratory chain generates the majority of ROS in aerobic cells by incomplete reduction of molecular O2 to 
H2O during oxidative phosphorylation, as well as during microsomal and peroxisomal oxidations [68].  
In addition, the production of ROS and RNS are also associated with a number of processes such as 
inflammation, infections and immune reaction [69]. Cigarette smoke contains free radicals such as 
nitric  oxide  and  mixtures  of  hydroquinones,  semiquinones  and  quinones,  which  can  induce redox 
cycling and are present in oxidative damage in smokers [3,65,70]. The mechanisms of NNK- and 
NNN-induced  oxidative  stress  are  not  well  understood.  However,  the  ability  of  NNK  to  induce 
oxidative stress was evident when increasing levels of 8-hydroxy-2'-deoxyguanosine (8-OHdG) adducts 
in lung tissues were detected after either oral administration or intraperitoneal injection of NNK into 
A/J mice and rats  [71–73]. 8-OHdG is a major pre-mutagenic lesion generated from ROS that is 
considered a marker of DNA oxidative damage. 8-OHdG is removed by Mmh/Ogg1 gene product,  
8-hydroxyguanine DNA glycosylase 1 (OGG1) through the BER pathway [74,75]. Although NNK-mediated 
ROS induce DNA lesions, another important aspect is ROS-mediated alteration of the microenvironment 
required  for  tumor  progression.  ROS  act  as  signaling  intermediates  for  many  normal  as  well  as 
pathological  cellular  processes.  Constant  activation  of  transcription  factors  such  as  nuclear  factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) appears to be one functional role of elevated 
ROS levels during tumor progression [76]. 
3.2.2. NNK and NNN Modulated Tumor Promotion and Progression: Creating a Microenvironment for 
Tumor Growth 
nAChRs consists of five subunits with homo- or hetero-pentamers used to form ligand-gated ion 
channels in the plasma membranes of certain neurons and on the presynaptic and postsynaptic sides of 
the neuromuscular junction [77]. Nicotine binds to the α subunit of nicotinic acetylcholine receptors 
(nAChRs) as an agonist by mimicking acetylcholine [78]. Nicotine has a higher affinity with α4β2 
heteromeric  nicotinic  acetylcholine  receptors  (α4β2nAChRs)  than  to  α7  homomeric  nicotinic 
acetylcholine  receptors  (α7nAChRs)  [79].  Accordingly,  the  biological  functions  of  α7nAChR  are 
increased in smokers, whereas the functions of α4β2nAChR are impaired. Unfortunately, α7nAChR is 
the  most  powerful  regulator  of  responses  that  stimulate  cancer  cells,  whereas  the  α4β2nAChR 
regulates predominantly inhibitory actions, resulting in an environment that provides selective support 
for the development and progression of cancer in vivo [80,81]. In addition to nicotine, NNN binds to 
heteromeric αβnAChRs and NNK to α7nAchR, with 5000 times and 1300 times higher affinity than 
that of nicotine, respectively [82,83]. High levels of the α7nAChR expression are found in small cell Cancers 2014, 6 
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lung carcinoma (SCLC), as well as in pulmonary neuroendocrine cells (PNECs), whereas heteromeric 
nAChRs  are  undetectable  [84,85].  In  non-small  cell  lung  carcinoma  (NSCLC)  cells  of  different 
histologic subtypes, both hetero- and homomeric nAChRs are found to be expressed at the same time [86]. 
NNK-  and  NNN-mediated  proliferative  potential  and  anti-apoptotic  effect  via  nAChRs  can  be 
alleviated by antagonists α-bungarotoxin (α-BTX) and mecamylamine, respectively. The role of nAChRs 
in nitrosamine-induced cancer can be further established by competition binding between endogenous 
ligand and nitrosamine. Recently an endogenous ligand for the α7nAChR has been identified as a 
secreted mammalian Ly-6/urokinase plasminogen activator receptor-related protein (SLURP) 1. In NNK 
treated  cells,  the  expression  levels  of  SLURP1  and  SLURP2  were  reduced.  Overexpression  of 
SLURP1 or SLURP2 in the cells reduced the nitrosamine-induced colony formation in soft agar while 
inhibiting the growth of NNK-transformed keratinocytes in mouse xenografts. In competition with 
NNK and NNN, SLURP1 bound to α7nAChR and SLURP2 bound to nAChRs expressing the α3 
subunit [83,87]. Although all nAChRs are cation channels, they regulate diverse cellular functions in a 
cell-type-specific manner. This functional diversity of nAChRs is also reflected in cancers of different 
cellular origins. 
Binding of NNK to α7nAChR activated voltage-gated Ca
2+ channels and caused influx of Ca
2+ into 
lung cells, resulting in membrane depolarization [88]. In turn protein kinase C, the serine/threonine 
kinase RAF1, the mitogen activated kinases extracellular signal-regulated kinase (ERK) 1 and ERK2, 
as well as the transcription factors FOS, JUN and MYC were activated, which led to the proliferation 
of PNECs or SCLC (Figure 2). α-BTX, a site-selective antagonist for the α7nAChR, and imipramine, a 
serotonin reuptake inhibitor, selectively inhibit this signal transduction pathway, indicating that the 
responses  to  NNK  were  facilitated  by  nicotinic  receptor-initiated  release  of  serotonin.  Exogenous 
addition  of  serotonin  activated  the  same  signaling  cascade  [89,90].  The  same  signal  cascade  also 
accounted for B-cell lymphoma 2 activation leading to NNK inhibited apoptosis in SCLC cells [91]. 
Although  histologic  types  of  lung  cancer  were  significantly  associated  with  cigarette  smoking, 
adenocarcinoma has a stronger association with smoking than other types of lung cancer, such as small 
cell carcinoma, squamous cell carcinoma and other NSCLC [92]. Consequently, smokers with chronic 
obstructive pulmonary disease (COPD) are at a particularly high risk of developing SCLC [93]. COPD 
is an inflammatory lung disease in which expiration of CO2 is decreased [94], while α7nAChR levels 
are upregulated [95]. In COPD, lung α7nAChR is sensitive to a high CO2 and low O2 environment [96–98]. 
NNK binds preferentially to the sensitized α7nAChR in the COPD lung instead of binding to β-AdrRs 
in  the  healthy  lung  [99,100].  In  addition,  phosphodiesterase  4,  an  enzyme  that  catalyzes  the 
intracellular breakdown of cAMP was found typically overexpressed in the COPD lung [101,102].  
The resulting deficiency in intracellular cyclic adenosine monophosphate (cAMP) deprives lung cells 
of their defense against hyperactive RAF1-mediated signaling. The pulmonary microenvironment in 
the COPD lung thus selectively favors the development of a neuroendocrine type of lung cancer under 
positive growth control by α7nAChR [81]. 
NSCLC  cell  lines  from  large-cell  carcinoma,  squamous-cell  carcinoma,  and  adenocarcinoma, 
express both hetero- and homomeric nAChRs. Phosphatidylinositol 3-kinase-AKT pathway and NF-κB 
are activated in response to NNK treatment in NSCLC cell lines, resulting in stimulation of proliferation 
and  inhibition  of  chemotherapy-induced  apoptosis  [103,104].  In  alveolar  type  II  cell-derived 
pulmonary adenocarcinomas (PACs), AKT-dependent nicotine-induced resistance to apoptosis was Cancers 2014, 6 
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due to the upregulation of survivin (also known as BIRC5) and X-linked inhibitor of apoptosis (XIAP; 
also known as BIRC4) [105], whereas α7nAChR-mediated stimulation of NSCLC cell proliferation is 
through activation of β-arrestin–SRC (Figure 2) [106]. In immortalized human bronchial epithelial 
cells, NNK activates ERK1 and ERK2 signal transduction pathway, signal transducer and activator of 
transcription 1(STAT1), NF-κB, and GATA binding protein 3 (GATA3), whereas NNN activates only 
GATA3 and STAT1 [107]. 
In addition, NNK is also an agonist of β-AdrRs and directly binds to them with high affinity. In the 
absence of penicillin and streptomycin that have been shown to interfere with β-AdrR signaling, NNK 
stimulated growth, and migration of small airway epithelial cells; the PACs derived from them are 
stimulated through β-AdrR-initiated cAMP signaling that transactivates the epidermal growth factor 
receptor (EGFR) (Figure 2) and cooperates with non-genomic estrogen receptor-β signaling [99,108,109]. 
A  nAChR-mediated  systemic  increase  in  adrenaline  and  noradrenaline,  which  are  β-adrenergic 
agonists,  may  additionally  stimulate  the  development  of  this  type  of  PAC.  Administration  of 
adrenaline in hamsters significantly promoted NNK-induced small airway-derived PAC, which was a 
strong argument for this hypothesis [81,100]. 
The inhibitory neurotransmitter γ-aminobutyric acid (GABA) inhibits β-AdrR-initiated cAMP signaling 
cascade at the level of adenylyl cyclase and effectively blocked DNA synthesis and cell migration.  
In turn, the release of GABA is regulated by α4β2nAChR, which is desensitized in smokers [110,111] 
and additionally downregulated in PACs by NNK, leading to a deficit in GABA [112]. The desensitization 
of this receptor is enhanced by estrogens and phyto-oestrogens [113]. The predominance of PAC in 
women and NNK-induced tumors in OGG knockout female mice may therefore, at least in part, be the 
result of estrogen impaired α4β2nAChR function. Moreover, NNK induced cell migration and invasion 
occurred in both SCLC and NSCLC through ERK1–ERK2-dependent phosphorylation of m-calpains 
and μ-calpains [114]. 
Genotoxicity and tumor promotion environment are two essential conditions for tobacco specific 
nitrosamines-induced cancer. Recently it was shown that the simultaneous expression of oncogenic  
K-ras, p53 knockdown, and mutant EGFRs were insufficient to confer a full malignant phenotype in 
bronchial epithelial cells [115]. NNK induces nearly identical numbers of mutation and comparable 
levels  of  mutagenic  DNA  adducts  in  both  susceptible  and  resistant  lungs  suggesting  a  pro-tumor 
environment  is  essential  for  tumor  progression.  The  upregulation  of  nAChRs  and  concomitant 
desensitization of α4β2nAChR in smokers shifts the balance in favor of α7nAChR signaling with 
strong direct and indirect stimulatory effects on cancer cells, whereas the release of GABA, which 
counteracts many of these effects, is reduced. This universal switch from balanced neurotransmission 
to cancer-stimulating neurotransmission is unstoppable once it occurs; blocking one signaling pathway 
or even removing the primary cancer will not stop the runaway α7nAChR train [81]. 
4. Conclusions 
Causal association between tobacco use and cancers is well established. Tobacco smoke contains 
7000 chemicals, and of which at least 60 are carcinogens. The human health risk caused by tobacco 
smoking is not limited to smokers, but also to non-smokers who are exposed to environmental tobacco 
smoke, causing cancers in adults and increasing cancers in children. Similar levels of carcinogenic Cancers 2014, 6 
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NNK exposure are found in tobacco smokers and smokeless tobacco users, therefore the smokeless 
tobacco is harmful and may not be a reduced risk substitute for tobacco smoking. 
Most  constituents  of  tobacco  smoke,  detoxified  or  neutralized  by  metabolizing  enzymes,  are 
converted to more water-soluble products, which can be excreted from the human body. However, 
during this process, certain reactive compounds may be formed as intermediates which may covalently 
bind to nucleophilic sites in DNA, causing DNA adducts. The DNA adducts can evade the repair 
system, and can cause miscoding during DNA replication resulting in a permanent mutation in the DNA 
sequence.  The  mutation can  occur in  a  cellular  oncogene or  in  a  tumor  suppressor gene,  altering  
the  normal  growth  control  mechanisms,  which  may  lead  to  uncontrolled  proliferation,  further 
mutations and cancer. 
Exposure to any type of tobacco is associated with, and/or increases the risk of, various cancers. 
Tobacco smoke contains a mixture of nicotine, carcinogens and toxicants. Nicotine is not a direct 
chemical carcinogen, however, it causes addiction leading to the chronic exposure to tobacco smoke 
that increases cancer risk for tobacco users. While carcinogens, such as nitrosamines, induce cancer by 
causing gene mutations and/or DNA and protein adducts, nicotine promotes cancer progression by 
activating signaling pathways that facilitate cancer cell growth, angiogenesis, migration, and invasion. 
The nicotine and carcinogen alliance is detrimental to human health, costs billions in direct medical 
care, causes loss of productivity, and is responsible for millions of preventable and premature deaths 
each year. 
A better understanding of the distinct mechanisms by which tobacco induces carcinogenesis may 
potentiate the discovery of new biomarkers, enhance the development of sensitive methods to identify 
trace  amounts  of  tobacco-specific  carcinogens,  facilitate  effective  epidemiologic  studies,  and  help 
guide the evolution of public health and health care policy toward implementing improved approaches 
for the prevention of tobacco-related cancers. 
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